We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Read MoreHide Full Article
Apellis Pharmaceuticals (APLS - Free Report) announced positive data from the late-stage GALE long-term extension study evaluating its marketed drug, Syfovre (pegcetacoplan injection), to treat patients with geographic atrophy (GA) secondary to age-related macular degeneration.
Per the data readout, presented at a recent medical conference, treatment with Syfovre in the GALE study preserved visual function at 36 months in the GA patients. Per Apellis, Syfovre is the only approved GA treatment to show a benefit on visual function in a prespecified endpoint.
Additionally, it was observed that patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month Syfovre treatment compared with patients from the sham crossover group, which met a prespecified microperimetry endpoint.
Please note that scotomatous points measure areas of the retina that have lost all light sensitivity and, therefore, are no longer functioning.
The stock gained 3.3% on Monday, Jun 10, in response to the positive GALE study data. Year to date, Apellis’ shares plunged 30.3% compared with the industry’s 5.9% decline.
Image Source: Zacks Investment Research
The phase III GALE extension study mostly enrolled patients who completed the late-stage OAKS and DERBY studies, positive results from which supported the approval of Syfovre for the GA indication.
Patients in the sham crossover group completed treatment with sham injections from months 0-24 in the phase III OAKS study and received Syfovre from months 24-36. Microperimetry was a key secondary endpoint measured only in the OAKS study, and therefore, patients who crossed over from the OAKS study were included in the long-term extension study.
Syfovre received FDA approval in February 2023 for the GA indication. It has the potential to be a best-in-class treatment for patients with GA, a disease that is the leading cause of blindness, affecting more than one million people in the United States and five million people worldwide.
The drug has witnessed robust initial uptake since its commercial launch in March 2023.Syfovre recorded sales of $137.5 million in the first quarter of 2024, which increased 20.3% sequentially, owing to continued strong demand, thereby driving revenues for the company. Apellis delivered more than 72,000 commercial vials and nearly 5,000 samples of Syfovre to doctors in the first quarter. As of Mar 31, 2024, the total number of drug doses delivered since launch was 250,000.
A marketing authorization application seeking approval of intravitreal pegcetacoplan to treat GA is currently under review in the EU and several other countries. A decision from the European Medicines Agency is expected no later than July 2024. Approvals from regulatory bodies in other countries are also expected in the current year.Potential approval of the drug in additional geographies will further boost the top line.
Apellis also currently markets pegcetacoplan under the brand name Empaveli/Aspaveli in the United States and EU, as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria. The drug is also approved in several other geographies for the same indication.
In the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. Year to date, shares of ALXO have plunged 41.8%.
ALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%.
In the past 30 days, the Zacks Consensus Estimate for Annovis’ 2024 loss per share has narrowed from $2.93 to $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.83 to $1.95. Year to date, shares of ANVS have plunged 65.2%.
ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.
In the past 30 days, the Zacks Consensus Estimate for Compugen’s 2024 earnings per share has increased from 2 cents to 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have gained 2.5%.
CGEN’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study
Apellis Pharmaceuticals (APLS - Free Report) announced positive data from the late-stage GALE long-term extension study evaluating its marketed drug, Syfovre (pegcetacoplan injection), to treat patients with geographic atrophy (GA) secondary to age-related macular degeneration.
Per the data readout, presented at a recent medical conference, treatment with Syfovre in the GALE study preserved visual function at 36 months in the GA patients. Per Apellis, Syfovre is the only approved GA treatment to show a benefit on visual function in a prespecified endpoint.
Additionally, it was observed that patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month Syfovre treatment compared with patients from the sham crossover group, which met a prespecified microperimetry endpoint.
Please note that scotomatous points measure areas of the retina that have lost all light sensitivity and, therefore, are no longer functioning.
The stock gained 3.3% on Monday, Jun 10, in response to the positive GALE study data. Year to date, Apellis’ shares plunged 30.3% compared with the industry’s 5.9% decline.
Image Source: Zacks Investment Research
The phase III GALE extension study mostly enrolled patients who completed the late-stage OAKS and DERBY studies, positive results from which supported the approval of Syfovre for the GA indication.
Patients in the sham crossover group completed treatment with sham injections from months 0-24 in the phase III OAKS study and received Syfovre from months 24-36. Microperimetry was a key secondary endpoint measured only in the OAKS study, and therefore, patients who crossed over from the OAKS study were included in the long-term extension study.
Syfovre received FDA approval in February 2023 for the GA indication. It has the potential to be a best-in-class treatment for patients with GA, a disease that is the leading cause of blindness, affecting more than one million people in the United States and five million people worldwide.
The drug has witnessed robust initial uptake since its commercial launch in March 2023.Syfovre recorded sales of $137.5 million in the first quarter of 2024, which increased 20.3% sequentially, owing to continued strong demand, thereby driving revenues for the company. Apellis delivered more than 72,000 commercial vials and nearly 5,000 samples of Syfovre to doctors in the first quarter. As of Mar 31, 2024, the total number of drug doses delivered since launch was 250,000.
A marketing authorization application seeking approval of intravitreal pegcetacoplan to treat GA is currently under review in the EU and several other countries. A decision from the European Medicines Agency is expected no later than July 2024. Approvals from regulatory bodies in other countries are also expected in the current year.Potential approval of the drug in additional geographies will further boost the top line.
Apellis also currently markets pegcetacoplan under the brand name Empaveli/Aspaveli in the United States and EU, as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria. The drug is also approved in several other geographies for the same indication.
Apellis Pharmaceuticals, Inc. Price and Consensus
Apellis Pharmaceuticals, Inc. price-consensus-chart | Apellis Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Apellis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech industry are ALX Oncology Holdings (ALXO - Free Report) , Annovis Bio (ANVS - Free Report) and Compugen (CGEN - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. Year to date, shares of ALXO have plunged 41.8%.
ALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%.
In the past 30 days, the Zacks Consensus Estimate for Annovis’ 2024 loss per share has narrowed from $2.93 to $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.83 to $1.95. Year to date, shares of ANVS have plunged 65.2%.
ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.
In the past 30 days, the Zacks Consensus Estimate for Compugen’s 2024 earnings per share has increased from 2 cents to 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have gained 2.5%.
CGEN’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%.